TBPH — Theravance Biopharma, Inc. Stock Price, Chart & AI Report

Neutral Feb 22, 2026 • 15:08 UTC The Motley Fool • Lawrence Rothman, Cfa

Irenic Dumps Most Papa John's Shares

Irenic Capital Management LP significantly reduced its Papa John's International position by approximately 70%, selling 748,592 shares in Q4 and retaining only 325,108 shares valued at $12.5 million. The stake now represents just 0.8% of the fund's AUM, dropping out of its top five holdings. Papa John's stock has underperformed the market, declining 30.7% over the past year while the S&P 500 gained 16.4%, amid struggling North American same-store sales.

PZZA ITGR SHC TBPH Papa John's International share sale fund divestment underperformance

Sentiment note

Listed as Irenic's third-largest holding ($51.7 million, 3.5% of AUM) but no specific news or context provided in the article regarding this position.

Neutral Jan 19, 2026 • 12:37 UTC GlobeNewswire Inc. • Researchandmarkets.Com

Neurogenic Orthostatic Hypotension (nOH) Global Clinical Trials Market Review 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status

ResearchAndMarkets.com released a comprehensive clinical trials review for Neurogenic Orthostatic Hypotension (nOH), analyzing global trial landscapes across regions, countries, phases, and sponsor types. The report identifies key trial locations, enrollment trends, and competitive dynamics to support strategic investment decisions in the nOH therapeutics market.

TBPH TAK IQV Neurogenic Orthostatic Hypotension clinical trials G7 countries E7 countries trial phases

Sentiment note

Company is listed as a prominent sponsor in nOH clinical trials, indicating active involvement in the therapeutic space, but no specific trial outcomes or developments are mentioned.

Neutral Aug 13, 2025 • 02:13 UTC The Motley Fool • Jesterai

Theravance Sales Jump 83 Percent

Theravance Biopharma reported Q2 2025 revenue of $26.2 million, driven by YUPELRI sales and a significant one-time gain from TRELEGY royalty asset sale. The company continues to focus on respiratory therapies and is advancing its ampreloxetine clinical program.

TBPH VTRS Theravance YUPELRI ampreloxetine respiratory medicine COPD

Sentiment note

Mixed financial performance with revenue growth and one-time gains, but modest underlying demand and continued operational losses

Unknown Jun 26, 2024 • 16:57 UTC Zacks Investment Research • Zacks Equity Research

AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer

Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.

AZN TBPH HRTX ARQT

Unknown Jun 26, 2024 • 15:28 UTC Zacks Investment Research • Zacks Equity Research

Here's Why You May Invest in Theravance (TBPH) Stock Now

Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.

TBPH RAPT ALGS VTRS

Unknown Jun 21, 2024 • 13:55 UTC Zacks Investment Research • Zacks Equity Research

Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know

The mean of analysts' price targets for Theravance Bio (TBPH) points to a 90.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

TBPH

Unknown Jun 12, 2024 • 15:30 UTC Zacks Investment Research • Zacks Equity Research

Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TBPH ZTS

Unknown May 14, 2024 • 16:06 UTC Zacks Investment Research • Zacks Equity Research

Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates

Theravance's (TBPH) first-quarter 2024 earnings beat estimates while revenues meet the same.

TBPH VTRS THRD

Unknown May 13, 2024 • 21:15 UTC Zacks Investment Research • Zacks Equity Research

Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 52.63% and 0.25%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

TBPH MDWD

Unknown May 8, 2024 • 23:30 UTC Zacks Investment Research • Zacks Equity Research

Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates

Catalent (CTLT) delivered earnings and revenue surprises of -125% and 3.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

CTLT TBPH

Unknown Apr 15, 2024 • 11:47 UTC Zacks Investment Research • Zacks Equity Research

Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?

Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

TBPH PRPH

Unknown Apr 3, 2024 • 15:30 UTC Zacks Investment Research • Zacks Equity Research

Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NKTR TBPH